🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A Olga Martínez-Sáez tampoco la pillamos desprevenida… 😜 ¿Cómo se relacionan las mariposas con la oncología? #beSOLTI

Orgulloso de 🏥 #Radiodiagnóstico Hospital Clínic 2r mejor Servicio del Estado español según el Merco 2024 y mejor de Catalunya

Finally out in ESMO Open the main findings of my ESMO - Eur. Oncology #Fellowship research project focused on the identification of predictors of response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in HR+/HER2- #breastcancer. What did we find? A thread 🧵

First, we compared NACT to NET in a clinical practice cohort of 186 patients, and confirmed that NACT is associated with higher rates of RCB-0/I than NET in stage I-IIIB HR+/HER2- BC. Both in the entire study cohort, then after propensity score matching to mitigate selection bias

When checking for clinicopathological and molecular factors predicting pathologic response, we found that PAM50 non-luminal subtypes at baseline were the only independent predictors of response to NACT, while for NET MMP11 mRNA levels were independently associated with RCB-II/III

We took into account 3 different response type, i.e. molecular responders (i.e. ROR-low and Ki67 10% after treatment) and pathologic responders. Using multiclass SAM, we revealed differential baseline gene expression differences among responders and non responders to NACT and NET

We then observed that both NACT and NET promote a molecular downstaging inducing molecular subtype shifting to luminal A or normal-like and to ROR-P-low-risk class

In addition, we found out that molecular downstaging or persistence of ROR-P-low or Luminal A subtype from baseline to surgery showed a trend for improved outcomes

More cool stuff can be found in the full publication available in OA at this link 👇authors.elsevier.com/sd/article/S20…, including cell lines experiments and further insights. It's been several years of my life spent on this project and likely many more to come, following up on this.

I would like to thank all the people involved in this study, but special thanks go to @prat_aleix who guided me through and pushed me to move forward, Fara Brasó Maristany for her teachings and suggestions, Tomás Pascual for giving me THAT database to "play with" in 2019, a life ago 🙏🙏🙏

Finally, a huge thank you to ESMO - Eur. Oncology and Evandro de Azambuja, MD, PhD, as without the #Fellowship programme I would have never had the possibility to do this research and probably to be where I am now. IDIBAPS Universitat de Barcelona Hospital Clínic

En Radioterapia del Hospital Clínic con iniciativas como reutilizar batas y peucs durante el tratamiento, avanzamos hacia una atención más consciente y respetuosa con el medio ambiente. 🌱 Gracias por ayudarnos a reducir los materiales de un solo uso! #ClinicVerd #OncRadClinic

YES, we are all excited about #SABCS24 but... What are you the most excited about? Here are the results of this week's poll with eliasegui 🤩 #beSOLTI

📢 Just happening now at #SABCS24 !! Presentation of #HER2DX ERBB2 mRNA Score in First-Line Metastatic HER2-Positive Breast Cancer Treated with Docetaxel, Trastuzumab and Pertuzumab: Correlative Analysis from CLEOPATRA Phase III Trial Javier Cortes MD PhD @prat_aleix #breastcancer

Dos minuts quaranta-sis segons d'amor a la brega. Aquest discurs tatuat d'humanisme desbordat i desbordant de la Blanca Llum Vidal, desarmada i perillosa. Ho recomana l'Erri de Luca: cal brindar pels empats i per les ics de les travesses. Per les meitats altres. Totes. ✊🏾❤️

REVEAL GENOMICS' team wishes you joy, peace, and success this holiday season and in the year ahead. #precisiononcology

Check out our new study: Identifying the best treatment choice for relapsing/refractory glioblastoma: a systematic review with multiple Bayesian network meta-analyses! Daniele Generali Estela Pineda Alberto Di Somma IDIBAPS Hospital Clínic Open access here👇🏻 doi.org/10.1093/oncolo…

Now that it’s official, I can finally celebrate: I’ve been awarded a Juan Rodés contract starting in 2025, ranking 1st in 🇪🇸! Ahora que es oficial, por fin puedo celebrarlo: me han concedido un contrato Juan Rodés a partir de 2025, ocupando el primer puesto en 🇪🇸! Instituto de Salud Carlos III (ISCIII)

Not yet registered for UPTODATE SUMMIT 2025? 📄 Check the programme and sign up👉 bit.ly/3EDxrFz See you on April 4th in Barcelona! 🚀 Don't miss out on this key event in lobular breast cancer, where international experts will discuss the latest developments.

#busGarraf en dissabte de BCN a tot arreu, aeroport, Vilanova, Sitges, Ribes....un bus del tercer món més que català....gent dreta, gent gran q puja a lhospital, maletes, caient a cada frenada....1 bus/hora!!! Vergonya no, el seguent #busgarraf #ajuntamentsantperederibes #tmb